News & AnalysisReCode Therapeutics scores $80m Series BReCode Therapeutics, a biopharmaceutical company, has raised $80 million in Series B financing.ByIris Dorbian21 October 2021•1 min readJavaScript is required to read this article. Please enable it in your browser and reload the page.DealsHealthcareBriefs